MDT (Medtronic plc)
Insider Trading Activity
Every open-market purchase and sale reported by MDT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Thierry Pieton | EVP & Chief Financial Officer | A | — | — |
| 2026-08-04 | Denise L. Blomquist | Chief Accounting Officer | MIXED | — | — |
| 2026-08-04 | Kweli Thompson | EVP & President, Neuroscience | MIXED | — | — |
| 2026-08-04 | Geoffrey Martha | Chairman and CEO | MIXED | — | — |
| 2026-08-04 | HARRY SKIP KIIL | EVP & President Cardiovascular | MIXED | — | — |
| 2026-08-04 | Michelle Quinn | EVP, GC and Secretary | A | — | — |
| 2026-08-04 | Michael Marinaro | EVP, Pres MedSurg and Americas | MIXED | — | — |
| 2026-08-04 | Matthew R. Walter | SVP, Chief HR Officer | MIXED | — | — |
| 2026-07-29 | Michelle Quinn | EVP, GC and Secretary | F | — | — |
| 2026-07-09 | Matthew R. Walter | SVP, Chief HR Officer | Sell | — | — |
| 2026-06-09 | HARRY SKIP KIIL | EVP & President Cardiovascular | Sell | — | — |
| 2026-06-08 | HARRY SKIP KIIL | EVP & President Cardiovascular | F | — | — |
| 2026-06-08 | Michael Marinaro | EVP, Pres MedSurg and Americas | F | — | — |
| 2026-06-08 | Denise L. Blomquist | Chief Accounting Officer | F | — | — |
| 2026-06-08 | Matthew R. Walter | SVP, Chief HR Officer | F | — | — |
| 2026-06-08 | Geoffrey Martha | Chairman and CEO | F | — | — |
| 2026-05-28 | Denise L. Blomquist | Chief Accounting Officer | M | — | — |
| 2026-05-28 | HARRY SKIP KIIL | EVP & President Cardiovascular | M | — | — |
| 2026-05-28 | Michael Marinaro | EVP, Pres MedSurg and Americas | M | — | — |
| 2026-05-28 | Geoffrey Martha | Chairman and CEO | M | — | — |
| 2026-05-28 | Brett A. Wall | EVP & Pres Neuroscience | M | — | — |
| 2026-05-28 | Matthew R. Walter | SVP, Chief HR Officer | M | — | — |
| 2026-05-04 | Matthew R. Walter | SVP, Chief HR Officer | F | — | — |
| 2026-04-29 | CRAIG ARNOLD | Director | MIXED | — | — |
| 2026-04-29 | SCOTT C DONNELLY | Director | MIXED | — | — |
| 2026-04-29 | Lidia Fonseca | Director | MIXED | — | — |
| 2026-04-29 | John P Groetelaars | Director | A | — | — |
| 2026-04-29 | RANDALL J HOGAN | Director | MIXED | — | — |
| 2026-04-29 | William R Jellison | Director | A | — | — |
| 2026-04-29 | Joon Sup Lee | Director | A | — | — |
| 2026-04-29 | Gregory P Lewis | Director | MIXED | — | — |
| 2026-04-29 | Kevin E Lofton | Director | MIXED | — | — |
| 2026-04-29 | ELIZABETH G NABEL | Director | MIXED | — | — |
| 2026-04-29 | Kendall J Powell | Director | MIXED | — | — |
| 2026-04-29 | Denise L. Blomquist | Chief Accounting Officer | MIXED | — | — |
| 2026-03-05 | Thierry Pieton | EVP & Chief Financial Officer | F | — | — |
| 2026-02-26 | HARRY SKIP KIIL | EVP & President Cardiovascular | MIXED | — | — |
| 2026-02-24 | Denise L. Blomquist | Chief Accounting Officer | G | — | — |
| 2026-02-02 | Denise L. Blomquist | Chief Accounting Officer | F | — | — |
| 2025-12-17 | Geoffrey Martha | Chairman and CEO | F | — | — |
| 2025-12-17 | Michael Marinaro | EVP, Pres MedSurg and Americas | F | — | — |
| 2025-12-17 | Brett A. Wall | EVP & Pres Neuroscience | F | — | — |
| 2025-12-09 | HARRY SKIP KIIL | EVP & President Cardiovascular | F | — | — |
| 2025-11-24 | Denise L. Blomquist | Chief Accounting Officer | G | — | — |
| 2025-11-21 | Gregory L Smith | EVP Global Ops & Supply Chain | Sell | — | — |
| 2025-09-05 | HARRY SKIP KIIL | EVP & President Cardiovascular | Sell | — | — |
| 2025-08-25 | William R Jellison | Director | Buy | — | — |
| 2025-08-21 | Michael Marinaro | EVP, Pres MedSurg and Americas | F | — | — |
| 2025-08-04 | Denise L. Blomquist | Chief Accounting Officer | MIXED | — | — |
| 2025-08-04 | HARRY SKIP KIIL | EVP & President Cardiovascular | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,150,778 | — |
| — | Executive Chairman | 577,632 | — |
| — | Director | 568,617 | — |
| — | Chairman & CEO | 434,032 | — |
| — | ExecVP Healthcare Policy & Reg | 333,638 | — |
| — | Chairman and CEO | 286,333 | — |
| — | EVP & Group Pres, Cardiac&Vasc | 190,640 | — |
| — | EVP & Global Ops and IT | 188,663 | — |
| — | EVP & Group Pres MDT Intl | 156,640 | — |
| — | Chief Operating Officer | 144,285 | — |
| — | EVP & GroupPres Restora Therap | 116,498 | — |
| — | Director | 115,672 | — |
| — | SrVP Gneral Counsel & Corp Sec | 106,843 | — |
| — | SVP & Pres CardioVascular | 99,410 | — |
| — | Sr VP, Intl Affairs | 98,368 | — |
| — | SVP & Pres CRDM | 97,790 | — |
| — | EVP, President, MITG | 88,818 | — |
| — | Director | 86,003 | — |
| — | EVP & Pres Neuroscience | 82,183 | — |
| — | SrVP Chief Talent Officer | 81,366 | — |
| — | Director | 78,694 | — |
| — | Director | 77,057 | — |
| — | SVP & Chief Medical & Science | 74,945 | — |
| — | SrVP Gneral Counsel & Corp Sec | 74,268 | — |
| — | Director | 68,882 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MDT quote page; the site-wide leaderboard is on the insider transactions hub.